Seer, Inc. Class A Common Stock SEER

Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.

• GlobeNewswire Inc. 28 jul

  Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting

  Seer, Inc. announced the re-election of all seven director nominees to its Board of Directors based on preliminary voting results from its 2026 Annual Meeting of Stockholders held on July 28, 2026. The company expressed confidence in its board's qualifications and commitment to advancing shareholder interests, while outlining its strategic focus on expanding platform utilization, securing biobank studies, advancing innovation, and scaling commercialization with cost discipline.

  

• GlobeNewswire Inc. 6 jul

  Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation Potential

  Seer, Inc. filed an investor presentation ahead of its July 28, 2026 Annual Meeting, highlighting progress against strategic goals including 62% CAGR in installed base growth, 36% decrease in annual cash burn since 2022, and a robust innovation pipeline. The company's Board unanimously recommends voting for its seven director nominees and opposes activist investors Bradley Radoff and Michael Torok's campaign to force an early sale, arguing their proposals lack actionable value creation ideas and their nominees lack relevant proteomics expertise.